{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:08Z","timestamp":1791593828131,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T00:00:00Z","timestamp":1347580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10875-012-9796-7","type":"journal-article","created":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T13:32:31Z","timestamp":1347629551000},"page":"33-37","source":"Crossref","is-referenced-by-count":38,"title":["Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin"],"prefix":"10.1007","volume":"33","author":[{"given":"Dean M.","family":"Wingerchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,14]]},"reference":[{"issue":"9","key":"9796_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"4","key":"9796_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med."},{"issue":"9451","key":"9796_CR3","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"issue":"4","key":"9796_CR4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","volume":"60","author":"JI O\u2019Riordan","year":"1996","unstructured":"O\u2019Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, et al. Clinical, CSF, and MRI findings in Devic\u2019s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60(4):382\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"9796_CR5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53(5):1107\u201314.","journal-title":"Neurology"},{"issue":"10","key":"9796_CR6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"8","key":"9796_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603\u20135.","journal-title":"Neurology"},{"issue":"Pt 7","key":"9796_CR8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u201361.","journal-title":"Brain"},{"issue":"Pt 5","key":"9796_CR9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235\u201343.","journal-title":"Brain"},{"issue":"24","key":"9796_CR10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"SR Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69(24):2221\u201331.","journal-title":"Neurology"},{"issue":"11","key":"9796_CR11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205(11):2473\u201381.","journal-title":"J Exp Med."},{"issue":"5","key":"9796_CR12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630\u201343.","journal-title":"Ann Neurol"},{"issue":"Pt 2","key":"9796_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(Pt 2):349\u201361.","journal-title":"Brain"},{"issue":"13","key":"9796_CR14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","volume":"78","author":"HS Patwa","year":"2012","unstructured":"Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009\u201315. doi: 10.1212\/WNL.0b013e31824de293 .","journal-title":"Neurology"},{"issue":"20","key":"9796_CR15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","volume":"78","author":"MI Leite","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601\u20137.","journal-title":"Neurology"},{"issue":"8","key":"9796_CR16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","volume":"18","author":"S Jarius","year":"2012","unstructured":"Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2012;18(8):1135\u201343. doi: 10.1177\/1352458511431728 .","journal-title":"Mult Scler"},{"key":"9796_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177\u201393.","journal-title":"Pharmacol Ther"},{"key":"9796_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","volume":"340","author":"Z Yu","year":"1999","unstructured":"Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227\u20138.","journal-title":"N Engl J Med"},{"key":"9796_CR19","doi-asserted-by":"crossref","unstructured":"Okada K, Matsushita T, Kira J, Tsuji S, Okada K, Matsushita T et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology. 74(2):177\u20138.","DOI":"10.1212\/WNL.0b013e3181c919ee"},{"key":"9796_CR20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","volume":"10","author":"DM Wingerchuk","year":"2008","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008;10:55\u201366.","journal-title":"Curr Treat Options Neurol."},{"key":"9796_CR21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878\u201386.","journal-title":"Ann Neurol"},{"issue":"12","key":"9796_CR22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00296-008-0611-y","volume":"28","author":"Y Ii","year":"2008","unstructured":"Ii Y, Shindo A, Sasaki R, Naito Y, Tanaka K, Kuzuhara S, et al. Reversible stenosis of large cerebral arteries in a patient with combined Sjogren\u2019s syndrome and neuromyelitis optica spectrum disorder. Rheumatol Int. 2008;28(12):1277\u201380.","journal-title":"Rheumatol Int"},{"issue":"5","key":"9796_CR23","first-page":"601","volume":"61","author":"Y Nakano","year":"2009","unstructured":"Nakano Y, Miyamoto K, Inatsugi Y, Suzuki H, Kusunoki S, Nakano Y, et al. Senile-onset recurrent myelitis with anti-aquaporin-4 antibody. Brain Nerve. 2009;61(5):601\u20134.","journal-title":"Brain Nerve."},{"issue":"7","key":"9796_CR24","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BAC Cree","year":"2005","unstructured":"Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270\u20132.","journal-title":"Neurology"},{"issue":"9","key":"9796_CR25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128\u201333.","journal-title":"Arch Neurol"},{"issue":"11","key":"9796_CR26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138.","journal-title":"Arch Neurol"},{"key":"9796_CR27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Madrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659\u201366.","journal-title":"Neurology"},{"key":"9796_CR28","doi-asserted-by":"crossref","unstructured":"Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2012. doi: 10.1016\/j.nrl.2012.03.014 .","DOI":"10.1016\/j.nrl.2012.03.014"},{"issue":"2","key":"9796_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J Bakker","year":"2004","unstructured":"Bakker J, Metz L. Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004;31(2):265\u20137.","journal-title":"Can J Neurol Sci"},{"issue":"19","key":"9796_CR30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"K Okada","year":"2007","unstructured":"Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med. 2007;46(19):1671\u20132.","journal-title":"Intern Med."},{"issue":"8","key":"9796_CR31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","volume":"72","author":"SM Magana","year":"2009","unstructured":"Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712\u20137.","journal-title":"Neurology"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-012-9796-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-012-9796-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-012-9796-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:14:52Z","timestamp":1559276092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-012-9796-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,14]]},"references-count":31,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["9796"],"URL":"https:\/\/doi.org\/10.1007\/s10875-012-9796-7","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,14]]}}}